NO20055941L - Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor - Google Patents

Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor

Info

Publication number
NO20055941L
NO20055941L NO20055941A NO20055941A NO20055941L NO 20055941 L NO20055941 L NO 20055941L NO 20055941 A NO20055941 A NO 20055941A NO 20055941 A NO20055941 A NO 20055941A NO 20055941 L NO20055941 L NO 20055941L
Authority
NO
Norway
Prior art keywords
inhibitor
pde5
pde4
composition
pde4 inhibitor
Prior art date
Application number
NO20055941A
Other languages
English (en)
Other versions
NO333501B1 (no
Inventor
Armin Hatzelmann
Christian Schudt
Thorsten Dunkern
Friedrich Grimminger
Hossein Ardeschir Ghofrani
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20055941L publication Critical patent/NO20055941L/no
Publication of NO333501B1 publication Critical patent/NO333501B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører den kombinerte administrasjon av en PDE4-inhibitor og en PDE5-inhibitor for behandlingen av en sykdom hvor fosfodiesterase 4 (PDE4) og/eller fosfodiesterase 5 (PDE5) aktivitet er skadelig.
NO20055941A 2003-05-22 2005-12-14 Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor NO333501B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011609 2003-05-22
PCT/EP2004/050869 WO2004103407A2 (en) 2003-05-22 2004-05-19 Composition comprising a pde4 inhibitor and a pde5 inhibitor

Publications (2)

Publication Number Publication Date
NO20055941L true NO20055941L (no) 2005-12-14
NO333501B1 NO333501B1 (no) 2013-06-24

Family

ID=33462087

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055941A NO333501B1 (no) 2003-05-22 2005-12-14 Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor

Country Status (23)

Country Link
US (3) US20060094723A1 (no)
EP (1) EP1628682B1 (no)
JP (1) JP2006528229A (no)
KR (1) KR20060012004A (no)
CN (1) CN1791429A (no)
AU (1) AU2004241749B2 (no)
BR (1) BRPI0410326A (no)
CA (1) CA2525946C (no)
CO (1) CO5660275A2 (no)
EA (1) EA012279B1 (no)
EC (1) ECSP056173A (no)
GE (1) GEP20084342B (no)
IL (1) IL171306A (no)
IS (1) IS8181A (no)
MA (1) MA27855A1 (no)
MX (1) MXPA05012302A (no)
NO (1) NO333501B1 (no)
NZ (1) NZ544040A (no)
RS (1) RS52730B (no)
TN (1) TNSN05265A1 (no)
UA (1) UA83041C2 (no)
WO (1) WO2004103407A2 (no)
ZA (1) ZA200508116B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
EP1755595A1 (en) * 2004-05-10 2007-02-28 Altana Pharma AG Use of roflumilast for the prophylaxis or treatment of emphysema
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
EA015382B1 (ru) * 2005-03-08 2011-08-30 Никомед Гмбх Применение рофлумиласта для лечения сахарного диабета типа 2
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
MX2007012711A (es) * 2005-04-19 2008-01-11 Nycomed Gmbh Roflumilast para el tratamiento de hipertension pulmonar.
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
ATE535244T1 (de) 2006-07-05 2011-12-15 Nycomed Gmbh Kombination aus atorvastatin mit einem phosphodiesterase-4-hemmer zur behandlung von entzündlichen lungenerkrankungen
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2010013925A2 (en) * 2008-07-31 2010-02-04 Dong-A Pharmaceutical. Co., Ltd. Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
CN103826638B (zh) * 2011-09-09 2015-11-25 Sk化学公司 含有pde5 抑制剂的减少皮肤皱纹的组合物
SG11201407919WA (en) * 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
US10058545B2 (en) * 2016-08-09 2018-08-28 Cipla Limited Method of treating pulmonary arterial hypertension
CN107648224A (zh) * 2017-10-31 2018-02-02 泰州中国医药城中医药研究院 一种治疗和预防心力衰竭药物及其在制药中的应用
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN108976107B (zh) * 2018-08-23 2021-03-23 南方医科大学 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
EP0706513B1 (de) 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
KR970705562A (ko) * 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
US6127363A (en) * 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
HU230154B1 (hu) 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
CZ20032491A3 (cs) * 2001-02-15 2004-01-14 Altana Pharma Ag Ftalazinonpiperidinové deriváty
JP2004530705A (ja) * 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのpde4インヒビター及びチオトロピウム又はその誘導体の組み合わせ
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient

Also Published As

Publication number Publication date
ECSP056173A (es) 2006-04-19
EA012279B1 (ru) 2009-08-28
US20100234382A1 (en) 2010-09-16
EP1628682B1 (en) 2013-09-25
IS8181A (is) 2005-12-14
CA2525946A1 (en) 2004-12-02
RS52730B (sr) 2013-08-30
BRPI0410326A (pt) 2006-05-23
AU2004241749B2 (en) 2010-03-25
NO333501B1 (no) 2013-06-24
JP2006528229A (ja) 2006-12-14
NZ544040A (en) 2009-03-31
UA83041C2 (ru) 2008-06-10
MA27855A1 (fr) 2006-04-03
EP1628682A2 (en) 2006-03-01
US20060094723A1 (en) 2006-05-04
KR20060012004A (ko) 2006-02-06
RS20050858A (en) 2007-12-31
AU2004241749A1 (en) 2004-12-02
GEP20084342B (en) 2008-03-25
MXPA05012302A (es) 2006-01-30
WO2004103407A3 (en) 2005-02-17
CA2525946C (en) 2013-01-29
EA200501690A1 (ru) 2006-06-30
US20120196867A1 (en) 2012-08-02
TNSN05265A1 (en) 2007-07-10
WO2004103407A2 (en) 2004-12-02
ZA200508116B (en) 2007-01-31
CN1791429A (zh) 2006-06-21
CO5660275A2 (es) 2006-07-31
IL171306A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
NO20055941L (no) Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
NO2007010I2 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
CY1111700T1 (el) Αναστολεις των νουκλεοζιτικων φωσφορυλασων και νουκλεοζιδασων
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
DE60330485D1 (de) Zur behandlung von diabetes
HUP0303082A2 (hu) Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk
DE69911448D1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
ATE283856T1 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ATE547104T1 (de) Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen
SE0302304D0 (sv) Novel compounds
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
HUP0500078A2 (hu) PDE inhibitort és leukotrién antagonistát tartalmazó kombinált gyógyszerkészítmény
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

MM1K Lapsed by not paying the annual fees